Live Breaking News & Updates on Helmsley Trust Professor
Stay updated with breaking news from Helmsley trust professor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biosense Webster Presents Late-Breaking Data From Inspire And Admire Clinical Trials At AF Symposium menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
FARAPULSE s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation News provided by Share this article Share this article Pioneering technology has demonstrated potential to improve safety for patients with paroxysmal atrial fibrillation and simplify procedures for physicians MENLO PARK, Calif., March 3, 2021 /PRNewswire/ - FARAPULSE Inc. today announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes them five times more likely to have a stroke than individuals with a regular heartbeat. The first patients were treated at New York s Mount Sinai Hospital by Dr. ....
First AF Patients Treated With Farapulse Pulsed Field Ablation System Pioneering technology may simplify procedures and improve outcomes for patients with paroxysmal atrial fibrillation March 3, 2021 Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal atrial fibrillation (AF). The first patients were treated at New York s Mount Sinai Hospital by Vivek Reddy, M.D., the Helmsley Trust Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the trial s principal investigator. ....